ETRA
Electra Therapeutics, Inc. Common stock (ETRA)
Healthcare • NASDAQ • $8.72-0.40%
- Symbol
- ETRA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $8.72
- Daily Change
- -0.40%
- Market Cap
- $549.21M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $15.50
- 52W Low
- $8.50
- Analyst Target
- $33.33
- Dividend Yield
- 0.00%
- Beta
- N/A
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
Company websiteResearch ETRA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.